[
    {
        "source_PMID": "9742977",
        "questions": [
            " What does intensive blood-glucose control with insulin or sulphonylurea therapy decrease in patients with type 2 diabetes?",
            " What may also reduce the risk of heart attacks?",
            " How many patients were recruited to this study?",
            " How many patients were recruited to UKPDS in 15 centres?",
            " How many overweight patients had newly diagnosed type 2 diabetes?",
            " What was the mean age of the patients?",
            " What was the median duration of a randomised controlled trial?",
            " How many patients were included in a Randomised Controlled Trial?",
            " What were the patients allocated metformin with?",
            " How many patients were allocated metformin?",
            " How many overweight patients were assigned intensive blood-glucose control with chlorpropamide?",
            " What were the primary outcome measures of the secondary analysis?",
            " How many non-overweight and overweight patients were allocated continuing sulphonylurea therapy alone?",
            " What was the mean glycated haemoglobin (HbA1c) in the supplementary randomised controlled trial?",
            " What was the median glycated haemoglobin (HbA1c) in the metformin group compared to?",
            " What percentage of patients allocated metformine had risk reductions of 32% for any diabetes-related endpoint?",
            " How much of a risk reduction was achieved for diabetes related death?",
            " What percentage of diabetes-related death was metformin associated with?",
            " What was the percentage of all-cause mortality?",
            " Which drug showed a greater effect than chlorpropamide, glibenclamide, or insulin for any diabetes related endpoint?",
            " What was the risk of diabetes-related death associated with early addition of metformin in sulphonylurea-treated patients?",
            " What was a 95% CI 2-275, p=0.039?",
            " A combined analysis of the main and supplementary studies showed what?",
            " What percentage of patients had diabetes-related endpoints?",
            " What was the risk reduction in patients with diabetes related endpoint?",
            " In 4416 patients, what did not show an increased risk in diabetes related death in patients treated with sulphonylurea and metformin?",
            " What does intensive glucose control with metformin seem to decrease in overweight diabetic patients?",
            " What is associated with less weight gain and fewer hypoglycaemic attacks than insulin and sulphonylurea?",
            " What may be the first-line pharmacological therapy of choice in these patients?",
            " What is the gain and fewer hypoglycaemic attacks than?"
        ]
    },
    {
        "source_PMID": "32891604",
        "questions": [
            " How did we evaluate the effect of multifactorial intervention on the onset and progression of diabetic kidney disease in patients with type 2 diabetes?",
            " What did we analyze the effects of intensified multifactororial intervention by step-wise intensification of medications and life-style modifications?",
            " What is the typical therapy treatment target?",
            " How many eligible diabetic kidney patients were eligible for therapy?",
            " What is a guideline-based standard care?",
            " How many patients in the J-DOIT3 cohort were randomly assigned to intensive therapy and conventional therapy?",
            " What was the median median length of treatment for diabetic kidney disease?",
            " What was the median age of a patient treated for kidney failure?",
            " What was a prespecified kidney outcome measure?",
            " How many kidney events occurred in the intensive therapy group?",
            " How many in the conventional therapy group were there?",
            " What type of analysis was carried out on the intention-to-treat population?",
            " How much reduction in kidney events was intensive therapy associated with compared to conventional therapy?",
            " What was associated with the change in HbA1c at one year from study initiation?",
            " How many patients were in the intensified multifactorial intervention group?",
            " What type of intervention significantly reduced the onset and progression of diabetic kidney disease compared to currently recommended care?"
        ]
    },
    {
        "source_PMID": "32215272",
        "questions": [
            " What is one of the most common chronic complications of diabetics?",
            " What causes nerve damage and muscle strength decrease in diabetic patients?",
            " What was the purpose of the study?",
            " How many diabetic neuropathic females were randomly selected?",
            " What group received resistance-aerobic training?",
            " How long did the experimental group receive resistance-aerobic training?",
            " How much of the heart rate reserve did the aerobic exercises contain?",
            " How much heart rate reserve did the aerobic exercises contain?",
            " How long was the rest interval between sets and 5-10 repetitions?",
            " After how many weeks of combined exercise training did the serum kinesin-1 level and aerobic endurance decline?",
            " What is combined exercise training?",
            " The upper body strength increased but was not significant?",
            " What body showed a significant strength increase?",
            " What can be useful from combined exercise training?",
            " What is required in this area?"
        ]
    },
    {
        "source_PMID": "30012135",
        "questions": [
            " What is the gold-standard treatment for bipolar disorder?",
            " What is highly effective in treating major depressive disorder and has anti-suicidal properties?",
            " Why are clinicians increasingly avoiding lithium?",
            " Nephrogenic Diabetes Insipidus occurs in 15-20% of what?",
            " What percentage of lithium users have a 2-3 times increased risk of CKD?",
            " What drug is associated with lower NDI risk in a cross-sectional study?",
            " How do we describe the methodology of a randomized controlled trial?",
            " What is a randomized controlled trial to treat lithium-induced NDI using atorvastatin?",
            " Where will we conduct a 12-week, double-blind placebo-controlled RCT?",
            " How many lithium users will be recruited?",
            " What is the urine osmolality of 18-85 years old?",
            " How long will atorvastatin be given to patients?",
            " What is aquaporin?",
            " What does AQP2 stand for?",
            " What is the aim of this clinical trial?",
            " What is CKD?",
            " What is AKI?",
            " When was the trial registered?"
        ]
    },
    {
        "source_PMID": "31295292",
        "questions": [
            " What is the first treatment line in the prevention of diabetic foot ulcer and future complications of diabetes?",
            " Previous studies and the International Working Group on the Diabetic Foot have described therapeutic footwear as a protective factor to reduce the risk of re-ulceration?",
            " What was the purpose of this study?",
            " What did we aim to reduce in patients with diabetic foot?",
            " When did we conduct a randomized controlled trial?",
            " How did we reduce the risk of re-ulceration?",
            " Where was the randomized controlled trial conducted?",
            " How many patients had a recently healed plantar ulcer?",
            " What were the patients randomized into?",
            " What type of footwear was used in the study?",
            " How long were the patients followed up?",
            " What was the primary outcome measure?",
            " What was the primary outcome measure for ulcers in the plantar aspect of the foot?",
            " How many patients were randomized to the control and experimental groups?",
            " The median follow-up time for both groups was how many weeks?",
            " What percentage of patients were intention-to-treat patients?",
            " How many patients in the control and experimental groups had ulcer recurrence?",
            " What percentage of diabetic patients were adherence to therapeutic footwear?",
            " The rigid rocker sole improved what in diabetes patients with polyneuropathy?",
            " What is the risk of plantar fasciitis in patients with polyneuropathy and DFU history?",
            " What is a 95% confidence interval for diabetic foot ulcers?",
            " What is the purpose of reducing the risk of plantar ulcer recurrence?",
            " Where is TRIAL REGISTRATION?"
        ]
    },
    {
        "source_PMID": "32621644",
        "questions": [
            " What type of disease is lithium associated with?",
            " What is the risk of incident chronic kidney disease among lithium users?",
            " There are limited randomized controlled trials for what type of NDI?",
            " What is a RCT for?",
            " What can existing therapies be poorly tolerated?",
            " How long did we conduct a double-blind pilot RCT?",
            " How old were the patients recruited between September 2017 and October 2018?",
            " What was the mean UOsm at 12 weeks adjusted for baseline?",
            " What was the difference in mOsm/kg in atorvastatin compared to placebo groups?",
            " What were the secondary outcomes of fluid intake and aquaporin-2 excretions at 12 weeks adjusted for baseline?",
            " What was the 95% CI of -190.34, 387.70?",
            " What did atorvastatin 20 mg/d not significantly improve among lithium users with NDI?",
            " How much effect size was observed for improvements in baseline UOsm at 12 weeks?",
            " What did atorvastatin 20 mg/d not significantly improve compared to placebo over a 12-week period?",
            " What may help to further assess the effects of statins on NDI?"
        ]
    },
    {
        "source_PMID": "32321301",
        "questions": [
            " What is the aim of this study?",
            " How many patients who had diabetes mellitus were included in the study.",
            " What type of diabetic retinopathy did the study examine?",
            " How many patients applied to the Health Sciences University Ulucanlar Eye Training and Research Hospital between January 2016 and January 2017?",
            " How many diabetes mellitus patients were evaluated in the study?",
            " How were mellitus patients evaluated?",
            " How were diabetic patients compared with healthy control group?",
            " What was a statistically significant difference found in the endothelial cell densitometer?",
            " What was found in the endothelial cell densitometer, coefficient of variation, and standard deviation measurements between diabetes mellitus patients and the control group?",
            " There was no statistically significant difference between 6A (hexagonality) and central corneal thickness measurements?",
            " What was a negative correlation between HbA1c levels and diabetes?",
            " What was the negative correlation between HbA1c levels and diabetes mellitus times and endothelial cell densitometer values?",
            " What was there a statistically significant difference between diabetic patients with the diagnosis of non-proliferative diabetic retinopathy?",
            " What was not statistically significant between the coefficient of variation, 6A, and central corneal thickness values?",
            " What was the endothelial cell densitometer in diabetes mellitus patients with the diagnosis of?",
            " What is the endothelial cell densitometer in diabetes mellitus patients with retinopathy lower than in healthy individuals?",
            " There is a negative correlation between what two things?",
            " Diabetes affects not only vascular tissues but also avascular cornea?"
        ]
    },
    {
        "source_PMID": "34889293",
        "questions": [
            " What is one of the most common complications of diabetes mellitus?",
            " What are the main clinical manifestations of DPN?",
            " How often does DPN lead to diabetic foot ulceration?",
            " What theory has a great effect on treating and preventing DPN?",
            " What is still lacking to evaluate the efficacy of moxibustion?",
            " How many diabetes mellitus patients with peripheral neuropathy will be recruited for this study?",
            " How many groups of patients will be randomly assigned to the moxibustion group and waiting group?",
            " How many groups are randomly assigned?",
            " How long is the trial?",
            " What is the follow-up period?",
            " The moxibustion group will take how many sessions per week?",
            " What is the primary outcome?",
            " What will be measured with algometry?",
            " Who is unaware of the assignment?",
            " What is a secondary outcome of the study?",
            " What is an evaluation of functional performance capacity with 6 minutes walking test?",
            " What is the name of the trial that will provide valuable insights on the efficacy of moxibustion in the management of diabetic peripheral neuropathy?",
            " When was the trial registered?"
        ]
    },
    {
        "source_PMID": "7587918",
        "questions": [
            " How many patients with NIDDM were randomly assigned to multiple insulin injection treatment?",
            " What did intensive glycemic control reduce the severity of?",
            " How many NIDDM patients were evaluated in the primary-prevention cohort?",
            " How many patients were randomly assigned to multiple insulin injection treatment group?",
            " What was the name of the group that randomly assigned patients?",
            " Which group was the most likely to have retinopathy?",
            " How many NIDDM patients showed urinary albumin excretions <unk> 300 mg/24 h?",
            " How often were the appearance and the progression of retinopathy, nephropathy and neuropathy evaluated?",
            " How often were complications evaluated over a 6-year period?",
            " What was defined as an increase of 2 or more steps in the 19 stages of the modified ETDRS interim scale for retinopathy?",
            " What are the three stages of nephropathy?",
            " What percentage of the development and progression in retinopathy after 6 years was the MIT group?",
            " How much was the CIT group's cumulative percentages of development and the progression in the primary-prevention cohort?",
            " What percentage of nephropathy did the MIT group have after 6 years?",
            " What was the CIT group's cumulative percentage of development and progression?",
            " How much of a difference was there between MIT and CIT in the primary prevention cohort?",
            " What percentage of the MIT group showed significant improvement in the nerve after 6 years?",
            " How much of the CIT group's improvement was in the primary-prevention cohort?",
            " What was the difference between MIT and CIT groups in the secondary-intervention group?",
            " What group showed significant improvement in nerve conduction velocities and vibration threshold?",
            " How long did the MIT group show significant improvement?",
            " What did the CIT group see significant deterioration in?",
            " In what group did postural hypotension and the coefficient of variation of R-R interval improve?",
            " In which group did the diabetic retinopathy, nephropathy, and neuropathy improve?",
            " In what group did diabetics deteriorate in the CIT group?",
            " What can intensive glycemic control by multiple insulin injection therapy delay the onset and progression of?",
            " What is the glycemic threshold to prevent the onset and the progression of diabetic microangiopathy?",
            " What is HbA1c <unk> 6.5%, FBG <unk> 110 mg/dl, and 2-h post-prandial blood glucose concentration <unk> 180 mg/l?"
        ]
    },
    {
        "source_PMID": "7598463",
        "questions": [
            " What trial demonstrated that intensive treatment of patients with IDDM can substantially reduce the onset and progression of diabetic retinopathy, nephropathy and neuropathy?",
            " What is the major risk associated with intensive treatment?",
            " Hypoglycemia is difficult but should be considered and recommended to most patients with what type of diabetes?",
            " If intensive treatment is impractical, any improvement in glycemic control is probably beneficial.",
            " What should be recommended to patients with non-insulin-dependent diabetes mellitus?",
            " What is NIDDM?",
            " What is the most common type of diabetic?",
            " How is insulin used in diabetics?"
        ]
    }
]